Liponex Inc. (TSX:LPX), a biopharmaceutical company specializing in developing advanced products related to High Density Lipoprotein (HDL), often called “good cholesterol,” today provided an update on its preparations for its Phase I/II clinical trial of its lead compound CRD5, being developed for the treatment of dyslipidemia and heart disease.
